Federal and State Investigators Probe Epic Systems' Tactics

Epic Systems, the privately held electronic health record vendor, is the subject of a broad federal and state inquiry into allegedly anticompetitive business practices, according to people contacted by Federal Trade Commission investigators who spoke to STAT News in a report published Aug. 14, 2026.

Epic Systems, the Wisconsin-based company whose software holds the medical records of a large share of hospitalized Americans, is the subject of a broad inquiry into its business practices by federal and state investigators. People who were contacted by Federal Trade Commission investigators described the scrutiny to STAT News, which reported on the inquiry on Aug. 14, 2026. The reporting centers on allegedly anticompetitive practices, including the company's use of non-disclosure agreements.

Epic is private. There is no ticker to reprice, no earnings call at which management will be asked about a subpoena, and no filing obligation that forces disclosure. That is precisely why an antitrust inquiry into the company is unusual, and why its consequences will be felt mostly in the accounts of other companies — the listed health IT vendors, analytics firms and app developers whose products either sit on top of Epic's software or compete with modules Epic sells itself.

Why a private software vendor draws antitrust attention

Electronic health record systems are the operating system of a modern hospital. Once a health system commits, the switching cost is enormous: years of implementation, retraining of clinicians, migration of decades of patient data. That stickiness is the source of the market power that antitrust enforcers look for. It is not illegal to be dominant. What regulators examine is conduct — whether a dominant firm uses contracts, pricing or technical control to keep rivals from reaching customers who would otherwise buy from them.

In health IT, the conduct questions tend to cluster around a few recurring themes:

• Interoperability and data access. Whether third parties can read from and write to the record on commercially reasonable terms, or whether access is throttled, delayed or priced in a way that favors the incumbent's own modules.
• App and integration restrictions. Whether independent software vendors can connect to the record without agreeing to terms that limit how they compete.
• Contract language. Non-disclosure agreements are ordinary commercial hygiene. They become an enforcement issue when regulators believe they suppress the flow of information customers and competitors would need to shop, complain or benchmark. STAT's reporting specifically notes NDA use as part of what is being reviewed.

None of that has been established as unlawful in this matter. An inquiry is a fact-finding stage; it can end in a closed file, a consent order, or litigation, and the distance between those outcomes is measured in years.

What a broad inquiry actually changes in the near term

The first practical effect of an investigation like this is discovery of a different kind: it produces a public record. Interviews with customers and competitors, document requests and, eventually, any complaint or settlement all put into the open the commercial terms of a market that has been largely opaque. For hospital chief information officers negotiating renewals, that visibility has value regardless of the legal outcome.

The second effect is behavioral. Dominant firms under active review usually become more accommodating at the margins — faster to grant interface access, more flexible on contract language, less aggressive in bundling. Rivals rarely say so publicly, but that loosening is often worth more to them commercially than any remedy a court eventually imposes.

The third is regulatory convergence. Federal information-blocking rules already obligate health IT developers to share electronic health information except in defined circumstances. An antitrust inquiry running alongside that framework raises the stakes on the same conduct from two directions at once: one asks whether data was improperly withheld, the other whether withholding it entrenched a monopoly. The involvement of state investigators, as reported, widens the number of venues in which those questions can be asked.

The read-through for listed health IT and digital health names

Investors cannot buy or short Epic. What they can do is reassess the companies whose addressable market is defined, in part, by what Epic permits. Digital health vendors selling scheduling, revenue-cycle tools, patient engagement, clinical documentation, imaging workflow and increasingly AI-based clinical assistants all depend on integration with the dominant record. A regulatory environment that pushes toward easier, cheaper, more standardized access expands the ceiling on those businesses. A regulatory environment that leaves the incumbent's gatekeeping intact keeps it where it is.

That is a slow-burning thesis, not a trading catalyst, and Friday's tape reflected nothing of the sort. Broad U.S. benchmarks closed marginally lower on Aug. 14, 2026: the SPDR S&P 500 ETF (NYSEARCA: SPY) finished at $776.34, down 0.20% from the prior close of $777.88 and inside a day range of $775.43 to $778.80. The Invesco QQQ Trust (NASDAQ: QQQ), the Nasdaq 100 proxy, closed at $731.07, off 0.14%, and the SPDR Dow Jones Industrial Average ETF (NYSEARCA: DIA) ended at $536.80, down 0.21%. Those are as of the last trade at 20:00 GMT, with the market closed. In other words, this was a quiet session, and news of a fact-finding inquiry into a private vendor is not the kind of headline that moves an index.

The precedent question hanging over enterprise software

The wider significance runs past health care. Antitrust theories built on switching costs, integration permissions and platform gatekeeping apply to any enterprise software category where one vendor becomes the system of record. If enforcers develop a workable case around a private company in a regulated industry — where the customer is a hospital, the data is a patient's, and the public interest argument is easy to articulate — the analytical template travels.

For hospital systems, the calculus is more immediate and more awkward. Many are deeply committed to Epic and have no realistic alternative in the medium term. They are simultaneously the alleged victims of any conduct at issue and the parties most exposed to disruption if a remedy forces changes to contracts or product architecture. Expect hospital trade groups to be conspicuously quiet.

What to watch from here

• Whether the inquiry becomes formal and public. A civil investigative demand made public, or a complaint filed, is the step that converts reported scrutiny into a defined legal proceeding with a docket and a timetable.
• Which state attorneys general surface. Multistate coordination materially raises the cost and duration of a defense and increases the odds of a negotiated set of conduct commitments.
• Contract behavior at the renewal table. Any softening of NDA terms or interface pricing would be the earliest observable evidence that the inquiry is having an effect.
• Commentary from listed integration partners. Vendors who sell into Epic-run hospitals are the ones with the clearest view of whether access terms are changing, and their earnings calls are where that will leak first.

Nothing in the current reporting establishes wrongdoing, and Epic has not been charged. What has changed is that the terms on which the largest record system in American medicine deals with everyone around it are now a subject of federal and state examination — and that alone reshapes the negotiating table.

Key facts

• Subject of inquiry: Epic Systems, a private electronic health record vendor
• Investigators: Federal Trade Commission plus state investigators
• Reported by: STAT News, Aug. 14, 2026, citing people contacted by FTC investigators
• Market context (last trade 20:00 GMT, Aug. 14, 2026): SPY $776.34 (-0.20%); QQQ $731.07 (-0.14%); DIA $536.80 (-0.21%)

Frequently asked questions

What is Epic Systems being investigated for?

According to STAT News, Epic Systems is the subject of a broad inquiry by federal and state investigators into allegedly anticompetitive business practices, including the company's use of non-disclosure agreements. People contacted by Federal Trade Commission investigators described the scrutiny. No wrongdoing has been established and Epic has not been charged.

Can investors buy Epic Systems stock?

No. Epic Systems is privately held, so there is no listed share class, no ticker and no public earnings disclosure. Any investment read-through has to come indirectly, through listed health IT vendors, analytics firms and digital health companies whose products integrate with or compete against Epic's software in hospitals.

Why would antitrust enforcers care about an electronic health record vendor?

Electronic health record systems carry very high switching costs — years of implementation, clinician retraining and data migration. That lock-in can create market power. Enforcers typically examine whether a dominant vendor uses contract terms, pricing or technical control over data access to keep competitors from reaching customers, rather than dominance itself.

How do non-disclosure agreements become an antitrust issue?

NDAs are routine in commercial contracts. They attract regulatory attention when enforcers believe they suppress information that customers or competitors need to compare products, benchmark pricing or raise complaints. STAT News reported that Epic's NDA use is among the practices being reviewed by investigators.

Did the news move the stock market?

There is no evidence of that, and Epic is private in any case. On Aug. 14, 2026, major U.S. benchmark ETFs closed modestly lower: SPY at $776.34, down 0.20%; QQQ at $731.07, down 0.14%; and DIA at $536.80, down 0.21%, based on the last trade at 20:00 GMT.

What would be the earliest sign the inquiry is having real effect?

Watch for a public civil investigative demand or a filed complaint, disclosure of which state attorneys general are involved, and any softening of contract terms or interface access pricing at hospital renewals. Comments from listed integration partners on earnings calls often surface such changes first.

Sources

• Epic’s alleged anticompetitive practices under scrutiny from federal, state investigators — STAT News

Photo: https://kaboompics.com/ · Pexels Licence — source